Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 in Metastatic Hepatocellular Carcinoma
NCT06852820Phase 2Recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in hepatocellular carcinoma (HCC). Started Jun 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06852820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852820.